Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK7 | Q8TDX7 | 15/20 | 0.59 |
| ▸ | SRC | P12931 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | HCK | P08631 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.46 |
| ▸ | MTOR | P42345 | 3/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.46 |
| ▸ | PRKDC | P78527 | 3/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24096557 | 1.00 | NEK7 (0.59) | NEK7SRCKDRLCKTEK | |
| SCHEMBL25793488 | 0.94 | NEK7 (0.57) | NEK7SRCKDRLCKTEK | |
| SCHEMBL24096776 | 0.90 | NEK7 (0.58) | NEK7SRCKDRLCKTEK | |
| SCHEMBL30320540 | 0.89 | NEK7 (0.73) | NEK7SRCKDRLCKTEK | |
| SCHEMBL24096572 | 0.89 | NEK7 (0.73) | NEK7SRCKDRLCKTEK | |
| SCHEMBL24096519 | 0.88 | NEK7 (0.63) | NEK7SRCKDRLCKTEK | |
| SCHEMBL30320619 | 0.88 | NEK7 (0.63) | NEK7SRCKDRLCKTEK | |
| SCHEMBL24096615 | 0.88 | NEK7 (0.62) | NEK7SRCKDRLCKTEK | |
| SCHEMBL25817908 | 0.86 | NEK7 (0.61) | NEK7SRCKDRLCKTEK | |
| SCHEMBL29484527 | 0.86 | NEK7 (0.80) | NEK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | NEK7 1/4885SRC 651/4885KDR 4072/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | NEK7 1/4885SRC 3388/4885KDR 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.